tnf aml

0:21:32

Sphingosine-1-phosphate signaling modulation for the treatment of acute myeloid leukemia (AML)

0:19:12

Neoplasien der Blutzellen - Teil 1 (Merkmale der Leukämien und Lymphome) - AMBOSS Auditor

0:04:10

Azacitidine, venetoclax & magrolimab in patients with newly diagnosed & R/R high-risk AML

0:02:11

Differentiation Syndrome in AML #AML #Hematology #Oncology #AcutePromyelocyticLeukemia

0:53:42

Dr Kamil Kranc: “Targeting RNA modifications & hypoxia signalling pathways to eliminate CSCs in AML”

0:05:17

Relevance of Serum Tumour Necrosis Factor-Alpha Measurement in Acute Leukaemia

0:04:17

Novel Agents Under Investigation for AML

0:03:34

Treosulfan + fludarabine vs busulfan + fludarabine in active AML post-alloHSCT

0:06:32

Immune Checkpoint Inhibitors for AML

0:29:43

T cell Product Attributes that Correlate with Clinical Efficacy in B-ALL

0:24:17

Immune correlates of TP53 mutational status in acute myeloid leukemia

1:09:13

Advancements in AML in Atlantic Canada

0:00:53

They turned a complaint into a viral win by going the extra mile—literally! Join Us For More... #t

1:00:49

Oh and Frahm - Querying Cytokine Signaling Networks in Myeloproliferative Neoplasms

0:03:01

T-cell engaging antibodies: novel combinations to overcome resistance

0:22:14

Immune Infiltration Correlates with TP53 Mutational Status in a Multi-cohort Acute Myeloid Leukemia

0:03:54

Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

0:19:11

Dr. Aaron Schimmer: Clonal hematopoiesis: A pathway to cancer, a pathway to heart disease

0:23:20

Armoring CAR-NK cells with secreted IL15 enhances anti-AML functionality

0:51:24

Immunosuppression via effeocytosis in the tumor microenvironment

0:42:23

Molecularly targeted therapies for cancer Part 2

0:37:51

What makes a stem cell a stem cell and how does it go bad? - John Dick, Gairdner Laureate Lecture

0:13:01

The North Face Transgrancanaria 2015 English Official video

0:06:08

Down Syndrome iPSC Model: Endothelial Perspective on Tumor Development | Oncotarget